LON:HZD - Horizon Discovery Group plc (HZD.L) Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 184.50
▲ +165.66 (879.30%)

This chart shows the closing price for HZD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Horizon Discovery Group plc (HZD.L) Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HZD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HZD

Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Horizon Discovery Group plc (HZD.L) in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 184.50.

This chart shows the closing price for HZD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Horizon Discovery Group plc (HZD.L). This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/11/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/11/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/9/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/7/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/5/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/6/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/5/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/4/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/29/2020Peel HuntReiterated RatingHold
6/30/2020Peel HuntLower Price TargetHoldGBX 171 ➝ GBX 108
6/3/2020Peel HuntReiterated RatingHold
4/27/2020Peel HuntReiterated RatingHold
4/20/2020Peel HuntReiterated RatingHold
4/7/2020Peel HuntReiterated RatingHold
3/27/2020Peel HuntReiterated RatingHold
3/5/2020Peel HuntReiterated RatingHold
2/4/2020Peel HuntReiterated RatingHold
1/27/2020Peel HuntDowngradeHold
1/10/2020Peel HuntReiterated RatingAdd
12/13/2019Peel HuntReiterated RatingAdd
12/5/2019Peel HuntReiterated RatingAdd
11/4/2019Peel HuntUpgradeAdd
9/16/2019Peel HuntUpgradeAddGBX 170.80
9/16/2019Peel HuntUpgradeAddGBX 170.80
9/9/2019Peel HuntReiterated RatingHold
9/2/2019Peel HuntReiterated RatingHold
8/1/2019Peel HuntReiterated RatingHold
7/22/2019Peel HuntReiterated RatingHold
7/15/2019Peel HuntReiterated RatingHold
7/3/2019Peel HuntReiterated RatingHold
6/12/2019Numis SecuritiesReiterated RatingBuyGBX 280
6/4/2019Peel HuntReiterated RatingHold
5/23/2019Peel HuntLower Price TargetHoldGBX 177 ➝ GBX 171
4/29/2019Numis SecuritiesReiterated RatingBuyGBX 280
4/29/2019Peel HuntReiterated RatingHoldGBX 177
4/2/2019Peel HuntReiterated RatingHold
3/12/2019Peel HuntReiterated RatingHold
1/28/2019Peel HuntReiterated RatingHold
1/7/2019Peel HuntReiterated RatingHold
12/17/2018Peel HuntReiterated RatingHold
12/6/2018Peel HuntReiterated RatingHold
11/1/2018Peel HuntReiterated RatingHold
10/3/2018Peel HuntReiterated RatingHold
9/17/2018Peel HuntReiterated RatingHold
9/17/2018Numis SecuritiesReiterated RatingBuy
9/4/2018Peel HuntReiterated RatingHold
8/29/2018Peel HuntReiterated RatingHold
8/20/2018Peel HuntLower Price TargetHoldGBX 181 ➝ GBX 177
8/3/2018Numis SecuritiesReiterated RatingBuy
8/1/2018Peel HuntReiterated RatingHold
7/20/2018Numis SecuritiesReiterated RatingBuy
7/3/2018Peel HuntReiterated RatingHold
5/31/2018Peel HuntReiterated RatingHold
5/10/2018Numis SecuritiesReiterated RatingBuyGBX 245
5/10/2018Peel HuntReiterated RatingHold
5/3/2018Peel HuntReiterated RatingHoldGBX 181
4/4/2018Peel HuntInitiated CoverageHold
3/20/2018Peel HuntInitiated CoverageHoldGBX 181
3/6/2018Numis SecuritiesReiterated RatingBuyGBX 300
2/20/2018Numis SecuritiesReiterated RatingBuyGBX 300
2/19/2018N+1 SingerLower Price TargetBuyGBX 250 ➝ GBX 230
2/1/2018Numis SecuritiesReiterated RatingBuyGBX 300
12/29/2017Numis SecuritiesReiterated RatingBuyGBX 300
9/27/2017Numis SecuritiesReiterated RatingBuyGBX 300
9/22/2017N+1 SingerBoost Price TargetBuyGBX 219 ➝ GBX 250
9/21/2017Numis SecuritiesReiterated RatingBuyGBX 300
9/8/2017Numis SecuritiesReiterated RatingBuyGBX 300
7/20/2017Royal Bank of CanadaBoost Price TargetSpeculative BuyGBX 220 ➝ GBX 245
7/19/2017Shore CapitalReiterated Ratingnot rated
7/3/2017Numis SecuritiesReiterated RatingBuyGBX 262
6/15/2017Numis SecuritiesReiterated RatingBuyGBX 262
6/15/2017N+1 SingerBoost Price TargetBuyGBX 194 ➝ GBX 219
5/31/2017Beaufort SecuritiesReiterated RatingSpeculative BuyGBX 200
5/30/2017Numis SecuritiesReiterated RatingBuyGBX 262
5/30/2017N+1 SingerReiterated RatingBuy
5/22/2017N+1 SingerReiterated RatingBuyGBX 194
5/22/2017Numis SecuritiesReiterated RatingBuyGBX 262
5/22/2017Panmure GordonReiterated RatingBuyGBX 205
5/9/2017N+1 SingerReiterated RatingBuyGBX 194
4/20/2017Panmure GordonReiterated RatingBuyGBX 205
4/4/2017Numis SecuritiesReiterated RatingBuyGBX 262
3/14/2017N+1 SingerReiterated RatingBuyGBX 194
3/14/2017Numis SecuritiesReiterated RatingBuyGBX 262
3/2/2017Numis SecuritiesReiterated RatingBuyGBX 262
2/15/2017Beaufort SecuritiesReiterated RatingSpeculative BuyGBX 200
1/25/2017Beaufort SecuritiesReiterated RatingSpeculative Buy
1/24/2017Panmure GordonReiterated RatingBuyGBX 205
1/24/2017Numis SecuritiesReiterated RatingBuyGBX 262
1/17/2017Beaufort SecuritiesReiterated RatingSpeculative BuyGBX 200
11/17/2016Beaufort SecuritiesReiterated RatingSpeculative Buy
11/16/2016Numis SecuritiesReiterated RatingBuyGBX 260
11/9/2016Numis SecuritiesReiterated RatingBuyGBX 260
11/9/2016Panmure GordonReiterated RatingBuyGBX 205
11/9/2016N+1 SingerReiterated RatingBuyGBX 194
11/2/2016Beaufort SecuritiesReiterated RatingSpeculative Buy
11/1/2016Numis SecuritiesReiterated RatingBuyGBX 260
11/1/2016Panmure GordonReiterated RatingBuyGBX 205
10/20/2016Beaufort SecuritiesReiterated RatingSpeculative Buy
10/19/2016Numis SecuritiesReiterated RatingBuyGBX 260
9/21/2016Beaufort SecuritiesReiterated RatingSpeculative Buy
9/20/2016N+1 SingerReiterated RatingBuyGBX 194
9/20/2016Numis SecuritiesReiterated RatingBuyGBX 260
9/20/2016Panmure GordonLower Price TargetBuyGBX 270 ➝ GBX 205
9/14/2016Beaufort SecuritiesReiterated RatingSpeculative Buy
9/13/2016Panmure GordonReiterated RatingBuyGBX 270
9/7/2016Numis SecuritiesReiterated RatingBuyGBX 252
9/2/2016Beaufort SecuritiesReiterated RatingSpeculative Buy
9/1/2016Numis SecuritiesReiterated RatingBuyGBX 252
9/1/2016Panmure GordonReiterated RatingBuyGBX 270
(Data available from 8/5/2016 forward)
Horizon Discovery Group plc (HZD.L) logo
Horizon Discovery Group plc, a cell engineering company, engages in the design, manufacture, and application of gene editing and gene modulation tools in the United Kingdom, the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company operates through Screening, Research Reagents, Diagnostics, and BioProduction segments. It provides custom-made and off-the-shelf (OTS) RNAi gene modulation reagents, CRISPR reagents, synthetic SGRNAs, OTS cell models, and custom cell engineering services. The company also offers pooled CRISPR screens; arrayed RNAi and CRISPR screens, drug screens, and immunology assays; and RNAi and CRISPR screening libraries; and human T-Cell CRISPR screening service to meet the requirements of immunology based research in drug discovery. In addition, it provides OTS gene-edited CHO cells and custom CHO cell lines, and custom CHO gene engineering services; and OTS cell-based reference standards, made to order reference standards, and custom cell-based reference standards to evaluate molecular assays on a research use basis. The company serves customers in academic research labs, biopharmaceutical and diagnostics companies, and contract research and manufacturing organizations. It sells its products through direct field sales channel and e-commerce platform. The company has a partnership with the Rutgers, The State University of New Jersey to develop and commercialize base editing, a gene editing technology; strategic collaboration with Mammoth Biosciences to develop CRISPR tools to provide engineered cell lines for the biopharmaceutical industry; and collaboration with St George's University Hospital, London, and the European Molecular Genetics Quality Network to develop reference material for non-invasive prenatal testing. Horizon Discovery Group plc was founded in 2007 and is headquartered in Cambridge, the United Kingdom.
Read More

Today's Range

Now: GBX 184.50
Low: 184.50
High: 184.75

50 Day Range

MA: GBX 45.20
Low: 3.94
High: 184.50

52 Week Range

Now: GBX 184.50
Low: 88.40
High: 200

Volume

50,000 shs

Average Volume

676,498 shs

Market Capitalization

£302.98 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Horizon Discovery Group plc (HZD.L)?

The following sell-side analysts have issued research reports on Horizon Discovery Group plc (HZD.L) in the last twelve months:
View the latest analyst ratings for HZD.

What is the current price target for Horizon Discovery Group plc (HZD.L)?

0 Wall Street analysts have set twelve-month price targets for Horizon Discovery Group plc (HZD.L) in the last year. has the lowest price target set, forecasting a price of £100,000 for Horizon Discovery Group plc (HZD.L) in the next year.
View the latest price targets for HZD.

What is the current consensus analyst rating for Horizon Discovery Group plc (HZD.L)?

Horizon Discovery Group plc (HZD.L) currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for HZD.

What other companies compete with Horizon Discovery Group plc (HZD.L)?

How do I contact Horizon Discovery Group plc (HZD.L)'s investor relations team?

Horizon Discovery Group plc (HZD.L)'s physical mailing address is 8100 Cambridge Research Park Beach Drive, CAMBRIDGE, CB25 9TL, United Kingdom. The company's listed phone number is +44-1223-976000. The official website for Horizon Discovery Group plc (HZD.L) is www.horizondiscovery.com.